The placental enzyme 11␤-hydroxysteroid dehydrogenase-2 (11␤-HSD2) transforms maternal cortisol to inactive cortisone. Fetal glucocorticoid excess due to reduced 11␤-HSD2 activity could make small preterm infants susceptible to early adrenal insufficiency when the maternal cortisol source is no longer sustained. We assessed whether placental 11␤-HSD2 activity is related to early adrenal insufficiency and postnatal clinical course in extremely low birth weight (Ͻ1000 g) infants. Mean gestational age of the 44 infants was 26.6 wk (range, 23.7-32.0), birth weight was 747 g (440 -981), and relative birth weight was Ϫ1.9 SD (Ϫ4.9 to 1.0). We determined placental 11␤-HSD2 activity, baseline, and ACTHstimulated cortisol and assessed illness severity by the Score of Neonatal Acute Physiology (SNAP). One standard deviation decrease in placental 11␤-HSD2 activity corresponded to a 1.85 (95% CI 0.55 to 3.14; p ϭ 0.006) unit increase in SNAP score and 2.9 mm Hg decrease in minimum mean arterial pressure (95% CI 0.3 to 5.6 mm Hg; p ϭ 0.03). Placental 11␤-HSD2 activity was not associated with cortisol concentrations, although the confidence interval of the ACTH-stimulated cortisol was close to zero: 1 SD increase corresponded to 17% (Ϫ18% to 49%) increase in ACTH-stimulated cortisol. Moreover, a 1 SD decrease in enzyme activity was associated with a hazard ratio for postnatal glucocorticoid treatment of 1.63 (95% CI 1.00 to 2.65); p ϭ 0.05. In ELBW infants, lower placental 11␤-HSD2 activity is associated with more severe early postnatal illness and hypotension. Although an association with baseline or ACTH-stimulated cortisol was not seen, possible relationships with other components of the hypothalamic-pituitary-adrenal axis remain to be determined. (Pediatr Res 59: 575-578, 2006) 
D uring recent years, indications for early postnatal glucocorticoid treatment in neonatal intensive care have undergone considerable changes. Alarming reports on adverse glucocorticoid effects on neurodevelopmental outcome in childhood (1-3) have initiated new guidelines pointing out that the benefits of this treatment may not outweigh the short-and long-term adverse effects (4, 5) . However, many severely ill preterm infants in intensive care have remarkably low cortisol concentrations (6) , and recent findings have suggested that some subgroups of infants, such as those exposed to maternal chorioamnionitis (7, 8) or at a high risk of chronic lung disease (9) , could benefit from early glucocorticoid therapy.
A key regulator of fetal cortisol exposure is the placental enzyme 11␤-HSD2, which converts excess maternal cortisol to inactive cortisone. The activity of this enzyme is reduced in growth-retarded preterm infants (10) , who are more prone to early adrenal insufficiency (7, 11) . Therefore, we set out to study whether reduced placental 11␤-HSD2 activity in ELBW infants is associated with early postnatal illness severity, adrenal function, and glucocorticoid administration.
SUBJECTS AND METHODS
Study population. We studied 44 ELBW infants born at Helsinki University Central Hospital, Helsinki, Finland. Gestational age was confirmed by ultrasound before 20 wk of gestation. Infants from multiple pregnancies were included only if they had clearly separate placentas. No mother received inhaled or systemic glucocorticoids other than betamethasone to enhance fetal maturation. The mean gestational age at birth was 26.6 wk (range, 23.7-32.0 wk), mean birth weight was 747 g (440 -981 g), and mean relative birth weight was Ϫ1.9 SD (Ϫ4.9 to 1.0 SD). Table 1 shows the clinical data. The infants and their placentas were weighed immediately after birth. Birth weight relative to gestational age and infant sex, expressed in SD units, was determined with reference to current Finnish standards (12) . Maternal hypertension during pregnancy was defined as systolic blood pressure Ն140 mm Hg, diastolic blood pressure Ն90 mm Hg, or a Ն30 mm Hg increase in systolic or Ն15 mm Hg increase in diastolic blood pressure. Preeclampsia was diagnosed when proteinuria of Ն0.3 g/d was present together with hypertension. Increased umbilical artery resistance was defined as Doppler flow velocitometry showing an umbilical artery resistance index of Ն2 SD above mean for gestational age (13) . The clinical diagnosis of chorioamnionitis was made by the practicing obstetrician, based on maternal fever, elevated CRP concentration, and fetal tachycardia. Betamethasone (12 mg intramuscularly twice at 12-or 24-h intervals, treatment repeated in 7-10 d) served as an antenatal glucocorticoid treatment when preterm birth was imminent. The diagnosis of gestational diabetes was based on oral glucose tolerance test, with venous plasma glucose exceeding 4.8 mmol/L (baseline), 10.0 mmol/L (1 h), or 8.7 mmol/L (2 h) (14) . SNAP score. To gain an index of neonatal illness severity, we used the Score for Neonatal Acute Physiology (SNAP) (15) . SNAP consists of 28 items describing derangements in different organ systems and correlates well with therapeutic intensity, nursing workload and mortality (15) . In addition to the SNAP calculated from data during the first 24 h after birth, we scored the clinical condition during the ACTH test by calculating a similar score for the corresponding 24-h period. Data collected for the SNAP score included minimum mean arterial pressure (occurring for at least a 30-min period), which was used as a separate variable in the data analyses. Although there are more recently developed scoring systems that may be more accurate predictors of mortality, we chose SNAP (15) because its better ability to discriminate across a wide range of sublethal pathology (15, 16) .
Biochemical assays. Immediately after birth, a sample of placental tissue was dissected, snap frozen in liquid nitrogen, and stored at -70°C until analyzed. Placental 11␤-HSD2 activity was determined as described (10) . Briefly, placental tissue not containing any fetal membrane was thawed and homogenized, the homogenate spun with the supernatant incubated in 1.0 mL phosphate buffer (0.1 mol/ L, pH 7.6) containing 0.5 g/L protein, 0.8 nmol/L NAD, and 0.2 mol/L cortisol, in a shaking water bath at 37°C. After 30 min, the conversion of cortisol to cortisone was stopped by adding 1.0 mL methanol, with samples evaporated under nitrogen. Seven milliliters of dichloromethane was added to the residues, the upper phase was removed, 2 mL of water added, and the tubes were mixed. The upper phase was again removed and the lower phase dried under nitrogen. To the dry residue, 40 L of 40% methanol was added. Twenty-five microliters of the solution was injected into the HPLC. The chromatographic conditions were as described (17) .
As a routine procedure of the neonatal intensive care unit, serum cortisol concentrations were measured by a standard immunoassay (Immuno I Immunoanalysator, Bayer Inc., Tarrytown, NY) at baseline (n ϭ 44) and 30 min after a low dose (0.06 g/kg) ACTH 1-24 stimulation (n ϭ 31) at the mean age of 1.6 (SD 1.1) days. During the study period (2000 -2002) , local indications for postnatal glucocorticoid therapy in ELBW infants included cortisol concentrations Ͻ80 nmol/L at baseline or Ͻ400 nmol/L after ACTH stimulation and hypotension not responding to conventional treatments.
Data analysis. Cortisol concentrations were right-skewed and logtransformed to normality. Linear regression was used to calculate correlation between variables. The effect of 11␤-HSD2 activity on early glucocorticoid administration was assessed by Cox regression with survival time recorded as age at postnatal glucocorticoid treatment (n ϭ 24), death (n ϭ 1), or 10 d (n ϭ 19), whichever occurred first. All regression equations were adjusted for gestational age and the time between the last antenatal betamethasone dose and birth. Adjustment for the time between last betamethasone and birth was performed by dividing the infants into three groups: 1) Ͻ12 h; 2) 12-72 h; 3) Ͼ72 h since last betamethasone or no betamethasone. Dummy variables were created for these groups to allow for possible nonlinear effects. The time limits were based on estimated proportion of glucocorticoid bioactivity caused by betamethasone during each period (18) .
The study protocol was approved by the Ethics Committee for Children and Adolescents and the Ethics Committee of Obstetrics and Gynecology, Helsinki University Central Hospital, Helsinki, Finland. An informed consent was signed by parents of all infants undergoing procedures not a part of routine clinical care. Table 1 presents the prenatal and neonatal characteristics of the study infants. As previously shown (10), placental 11␤-HSD2 activity showed an inverse correlation with gestational age (r ϭ Ϫ0.47,p ϭ 0.001 for activity per milligram placental protein and r ϭ Ϫ0.41, p ϭ 0.003 for total placental activity) and a positive correlation with relative birth weight (r ϭ 0.33, p ϭ 0.05 and r ϭ 0.56, p ϭ 0.001, respectively) but was unrelated to maternal preeclampsia, hypertension, impaired umbilical artery flow, diabetes, or clinically diagnosed chorioamnionitis. There was no interaction between the effects of relative birth weight and gestational age on placental 11␤-HSD2 activity. Administration of the last betamethasone dose between 12 and 72 h before birth (n ϭ 9) was associated with higher total placental 11␤-HSD2 activity [mean difference, 0.75 SD; 95% confidence interval (CI), 0.05-1.46 SD; p ϭ 0.04].
RESULTS
Low total placental 11␤-HSD2 activity was associated with more severe postnatal clinical condition as assessed by the SNAP score, with a 1 SD decrease in enzyme activity corresponding to a 1.81 (95% CI, 0.37-3.24; p ϭ 0.01; Fig. 1 ) unit increase in SNAP score on d 1 and 1.85 unit (0.55-3.14; p ϭ 0.006) increase on the day of the ACTH test. A high SNAP score was in addition predicted by low relative birth weight: a 1 SD decrease in birth weight was associated with a 1.27 unit (95% CI, Ϫ0.03 to 2.56; p ϭ 0.05) increase in SNAP score on d 1 and 1.73 unit (0.61-2.85; p ϭ 0.003) on the day of the ACTH test. SNAP score was unrelated to gestational age or time after last antenatal betamethasone dose. Low placental 11␤-HSD2 activity was also related to hypotension on the day of the ACTH test: a 1 SD decrease in enzyme activity was associated with a 2.9 mm Hg decrease in minimum mean arterial pressure (95% CI, 0.3-5.6 mm Hg; p ϭ 0.03), which ‡ The number includes one infant of a mother with type-1 diabetes and six infants of mothers with gestational diabetes.
The number includes five cesarean sections during labor. ¶ Geometric means, with 25th and 75th percentiles in parentheses. 576 was in turn associated with lower baseline (r ϭ 0.38; p ϭ 0.02) and ACTH-stimulated (r ϭ 0.36; p ϭ 0.04) cortisol. However, placental 11␤-HSD2 activity was not associated with cortisol concentrations: a 1 SD increase in total 11␤-HSD2 activity corresponded to a 12% (95% CI, Ϫ18 to 54%) increase in baseline cortisol and 17% (Ϫ8 to 49%) increase in ACTH-stimulated cortisol. Yet, the lower the 11␤-HSD2 activity was, the more likely was the infant to receive early postnatal glucocorticoid treatment: a 1 SD decrease in enzyme activity was associated with a hazard ratio for glucocorticoid treatment of 1.63 (95% CI, 1.00 -2.65; p ϭ 0.05). Adjusting for preeclampsia, hypertension, impaired umbilical artery flow, diabetes, or clinically diagnosed chorioamnionitis did not affect the results. The time between birth and the ACTH test was not associated with baseline or ACTH-stimulated cortisol or rise over baseline (all p Ͼ 0.2)
DISCUSSION
We found that ELBW newborns with low placental 11␤-HSD2 activity had a more severe early postnatal clinical course and lower blood pressure and were more likely to receive early glucocorticoids, all of these findings being consistent with decreased adrenal function. Hypotension in particular is a well-known sign of early adrenal insufficiency (19 -21) . We also found that lower blood pressure was associated with lower cortisol concentrations, further strengthening this relationship. We did not find a significant relationship of placental 11␤-HSD2 activity with cortisol concentrations. However, the wide variation in baseline and ACTH-stimulated cortisol concentrations may have limited our ability to detect such an association in a study of this size.
Previously, early adrenal insufficiency has been linked with illness severity in a study showing an association between decreased ACTH-stimulated cortisol and a higher SNAP score in VLBW infants (6) . A specific link with hypotension has been supported by a number of findings, including lower random cortisol concentrations in infants who require inotropic medication (19) and an association between mean arterial pressure and cortisol pulse frequency and secretory rate (20) . These findings are paralleled by an association between lower urinary cortisol excretion with hypotension and cardiovascular dysfunction in a baboon model for severely preterm birth (22) . A defect at the level of the adrenal glands was supported by a study of 137 VLBW infants showing that, in hypotensive infants, stimulation with 1 g/kg corticotrophin-releasing hormone (CRH) at age 7 d was associated with a lower cortisol response despite a higher elevation in ACTH concentrations (21) .
A number of different ACTH doses has been used in previous studies of adrenal function in premature infants, ranging from doses such as 3.5 g/kg, designed to assess the maximal capacity of the adrenal cortex (7), to low doses such as the 0.06 g/kg in our study. We chose this dose because lower doses have been suggested to be more sensitive in detecting early adrenal insufficiency (23) , although only limited data are available at this point. This dose parallels the standard 1 g/1.73 m 2 dose used in adult low dose testing. However, even the low-dose ACTH test may be less sensitive than more cumbersome tests such as CRH challenge (24), and the lack of association in the present study could also be due to the dose used.
During normal gestation, placental 11␤-HSD2 activity permits passage of a low percentage of maternal cortisol to the fetus, which suppresses the fetal HPA axis for most of the gestation (25) . However, sufficiently low glucocorticoid exposure is important for the development of the fetal hypothalamic-pituitary-adrenal axis (25), a prerequisite for adequate postnatal glucocorticoid response. It is thus conceivable that reduced 11␤-HSD2 activity and the accompanying increased fetal exposure to maternal cortisol could result in adrenal insufficiency after birth when the maternal cortisol source is no longer sustained. Conversely, increased placental 11␤-HSD2 activity would be expected to decrease fetal exposure to maternal cortisol and facilitate adequate postnatal adrenal response.
High-dose postnatal glucocorticoid treatment has substantial adverse effects (1) (2) (3) (4) (5) . However, recent studies have identified high-risk subgroups in which the benefits of the treatment could potentially overshadow the side effects. A metaanalysis comprising 1721 infants concluded that survival without cerebral palsy, assessed at a mean age of 36 mo, was dependent on the a priori risk of chronic lung disease: at a risk exceeding 65%, glucocorticoid treatment increased cerebral palsy-free survival (9) . In a fresh report, the beneficial effect of early hydrocortisone on survival without chronic lung disease at 36 postmenstrual weeks was confined to infants whose pretreatment baseline cortisol was below median (26) . Low-dose hydrocortisone replacement with an initial dose of 1 mg/kg reduced the chance of chronic lung disease in infants exposed to histologic chorioamnionitis (7, 8) , a condition associated with reduced placental 11␤-HSD2 expression and activity (27) . Although the dose was designed to mimic the stress-induced physiologic glucocorticoid synthesis that could improve the long-term safety profile, the effects of this dosage 
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on neurodevelopmental outcome are not known. Nevertheless, these findings call for further research to identify possible subgroups of small preterm infants who might benefit from low-dose glucocorticoid replacement (7, 8) or therapy with pharmacological doses (9) . Our present findings suggest that infants who have suffered from conditions associated with low placental 11␤-HSD2 activity, such as intrauterine growth restriction (10, 11) or histologic chorioamnionitis (27) , constitute a promising candidate population for such studies.
